Evaluation of Second-Line Anti-VEGF after First-Line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter “SLAVE” Study

Background: The optimal anti-angiogenic strategy as second-line treatment in RAS wild-type metastatic colorectal cancer (mCRC) treated with anti-EGFR (Epidermal Growth Factor Receptor) based first-line treatment is still debated. Methods: This multicenter, real-world, retrospective study is aimed at...

Full description

Saved in:
Bibliographic Details
Published in:Cancers (Basel)
Main Authors: Parisi, Alessandro, Cortellini, Alessio, Cannita, Katia, Venditti, Olga, Camarda, Floriana, Calegari, Maria Alessandra, Salvatore, Lisa, Tortora, Giampaolo, Rossini, Daniele, Germani, Marco Maria, Boccaccino, Alessandra, Dell’Aquila, Emanuela, Fulgenzi, Claudia, Santini, Daniele, De Tursi, Michele, Tinari, Nicola, Di Marino, Pietro, Lombardi, Pasquale, Roselló Keränen, Susana, Huerta Álvaro, Marisol, Zurlo, Ina Valeria, Corsi, Domenico Cristiano, Emiliani, Alessandra, Zanaletti, Nicoletta, Troiani, Teresa, Vitale, Pasquale, Giampieri, Riccardo, Merloni, Filippo, Occhipinti, Mario Alberto, Marchetti, Paolo, Roberto, Michela, Mazzuca, Federica, Ghidini, Michele, Indini, Alice, Garajova, Ingrid, Zoratto, Federica, Delle Monache, Simona, Porzio, Giampiero, Ficorella, Corrado
Format: Artigo
Language:Inglês
Published: MDPI 2020
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7281759/
https://ncbi.nlm.nih.gov/pubmed/32429380
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12051259
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items